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The measurement of central blood pressure has generated interest as
a tool in predicting cardiovascular events. The purpose of this article is
to review the meaning and measurement of the central blood pressure
and consider its potential value as an index of the antihypertensive
response. Indirect estimation of central aortic pressures is obtained by
the study of the radial pulse wave compared with a central pulse wave
contour measured at the carotid or femoral artery level. The sum of the
forward pressure wave created by ventricular contraction and of the
reﬂected pressure wave from the peripheral arterial system produce
the peak systolic blood pressure in the aorta. Measurement of the
peripheral reﬂected-wave contribution to aortic blood pressure can be
quantiﬁed as the augmentation index. Also, the increase in the rapidity
of this travelling wave can be measured as the pulse wave velocity.
These 2 parameters are considered to be valid indices of the periph-
eral arterial stiffness. Along with the calculation of systolic and dia-
stolic aortic pressures, these measurements can give a better
understanding of the actual central blood pressure to which core or-
gans like heart, brain, and kidneys are submitted. There is tantalizing
evidence for the potential value of central blood pressure as a useful
index of antihypertensive action, but until clear evidence is obtained,
its use should continue to be considered exploratory.Received for publication September 3, 2013. Accepted March 9, 2014.
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ORESUME
La mesure de la pression arterielle centrale a suscite l’interêt comme
outil de prediction des evenements cardiovasculaires. Le but de cet
article est de passer en revue la signiﬁcation et la mesure de la
pression arterielle centrale, et d’examiner sa valeur potentielle comme
indice de la reponse antihypertensive. L’estimation indirecte des
pressions aortiques centrales est obtenue par l’etude de l’onde de
pouls radiale qui est comparee au contour de l’onde de pouls centrale
mesuree au niveau de la carotide ou de l’artère femorale. La somme
de l’onde de pression anterograde creee par la contraction ventricu-
laire et de l’onde de pression reﬂechie provenant du système arteriel
peripherique produit la pression arterielle systolique maximale dans
l’aorte. La mesure de la contribution de l’onde reﬂechie peripherique à
la pression arterielle aortique peut être quantiﬁee en tant qu’indice
d’augmentation. Aussi, l’augmentation de la rapidite de cette onde
progressive peut être mesuree en tant que vitesse de l’onde de pouls.
Ces 2 paramètres sont consideres comme etant des indices valables
de la resistance arterielle peripherique. Outre le calcul des pressions
systoliques et diastoliques aortiques, ces mesures peuvent offrir une
meilleure comprehension de la pression arterielle centrale actuelle à
laquelle les organes principaux comme le cœur, le cerveau et les reins
sont soumis. Il existe des donnees scientiﬁques interessantes sur la
valeur potentielle de la pression arterielle centrale comme indice utile
de l’action antihypertensive, mais jusqu’à ce que des donnees scien-
tiﬁques claires soient obtenues, son utilisation devrait encore être
consideree de manière exploratoire.Since its introduction more than a century ago, brachial artery
measurement of blood pressure (BP) has been performed for
the diagnosis of hypertension and follow-up of its treatment.
Compelling evidence has supported the value of higher levels
of brachial artery BP as a strong risk factor for heart disease
and strokes1 and have shown that its reduction using anti-
hypertensive medication is associated with an improvement in
prognosis.2 There is growing evidence that measurement ofcentral (aortic) BP, which is the pressure directly exerted on
the brain, heart, and kidneys, is different from the BP
measured in the arm, because of an ampliﬁcation effect that
increases the central BP. Hypertension is characterized by a
reduction in the calibre and number of small peripheral ar-
teries with an increase in mean arterial pressure, which is a
product of cardiac output and peripheral vascular resistance.3
These peripheral arteries are muscular, with a high proportion
of collagen ﬁbres and therefore are less distensible. In com-
parison, aortic and carotid arteries are predominantly made of
elastin ﬁbres. The arterial wall of these large arteries will
permit ﬁlling during systole by distension and will push blood
forward in a steady ﬂow during diastole as the artery recoils.
Therefore, arterial stiffness is lowest in the elastic ascending
and thoracic aorta and highest in distal arteries, such as the
tibial artery. Progressive loss of elasticity is encountered withpen access under CC BY-NC-ND license.
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pulse pressure (PP) in peripheral arteries.3 The pressure wave
generated by the left ventricle travels down the arterial tree
and then is reﬂected back centrally at the arterial-arteriolar
junction. Consequently, the total pressure waveform in the
aorta becomes the sum of the forward travelling waveform
generated by the left ventricle and the backward reﬂected wave
from the peripheral muscular and stiffer arteries. The back-
ward (reﬂected) wave causes an increase in the central peak
systolic BP, generating an increased PP. This increase in total
aortic PP is called the augmentation pressure (Fig. 1) and is
expressed as a percentage of the total pressure by the
augmentation index (AIx). Arterial stiffness of limb vessels
rapidly increases with distance from the heart, leading to a
narrower wave with greater systolic BP. As a result, brachial
systolic BP and PP are greater than central pressures in young
individuals, whereas diastolic BP is constant.4 Hypertension,
high lipid levels, and smoking all lead to increase of the central
BP.5 With aging, there is a disappearance of the PP gradient
along the arterial tree, leading to greater central BP because of
a more pronounced stiffening of the central rather than pe-
ripheral arteries.4Measurement of Central BP and Prognostic
Value
Central pressures are derived from noninvasive techniques
of measurement of radial or carotid pulses, and a validated
generalized transfer function is used to estimate central pres-
sures from the peripheral signal.6 These involve applanation
tonometry, in which transcutaneous pressure transducers at
the end of a probe obtain pressure waveforms that are almost
identical to those obtained using intra-arterial measurement.7
This technique is suitable for radial, carotid, or femoral ar-
teries. The carotid waveform is then used as a surrogate for
that of the aorta. Another method is a mathematical
description of the charge from the input to output signals to
derive an aortic waveform from measurements obtained at the
radial artery. Computerized programs then adjust for heart
rate, height, and age. Hence, central systolic BP, diastolic BP,
and PP are obtained and indices of arterial stiffness such as
AIx and pulse wave velocity (PWV) are estimated.8 The
general transfer functions of applanation tonometry have aFigure 1. The augmentation index is a ratio calculated from the blood
pressure waveform (augmentation index ¼ D P/pulse pressure). It is a
measure of the enhancement (augmentation) of central aortic
pressure by a reﬂected pulse wave (shown in green in the graph).
P, pressure. Reproduced with permission from USCOM.range of error, but it is less than for standard brachial cuff
pressure with a sphygmomanometer or an oscillometric de-
vice.9 Intrinsic variations in the measurements provided by
different instruments are possible and can be operator-
dependent.
The measurement of the AIx, which is a quantiﬁcation of
the arterial wave reﬂection on total BP, can vary with changes
in heart rate, cardiac contractility, and age. PWV is the
measurement of aortic pulse velocity; it is assessed by
measuring the distance between 2 arteries (usually the carotid
and femoral arteries) and dividing by the transit time. Greater
arterial stiffness, which means less compliant arteries, will
result in quicker wave travel to and from the periphery. PWV
has emerged as a better marker of arterial stiffness, because of
its relative ease of measurement and reliability, although some
variability has been encountered in different types of pop-
ulations, with age and different BP levels. It is not inﬂuenced
by smoking, dyslipidemia, or sex, but to some extent by heart
rate and diabetes.10 Mitchell and colleagues,11 in a prospective
study of 2232 participants in the Framingham Heart Study
after a mean follow-up of 7.8 years, concluded that the best
individual predictor of a ﬁrst major cardiovascular (CV) event
by a pulsatile hemodynamic measure is the PWV (Fig. 2).
Vlachopoulos et al. conducted a systematic review of 15,877
subjects and concluded that aortic PWV is a strong predictor
of future CV events and all-cause mortality and has a pre-
dictive value independent of classic CV risk factors and other
potential confounders.12 For total CV events and CV mor-
tality, the relative risk of a high PWV was greater in high-risk
populations compared with low-risk populations. These
ﬁndings suggest that measurement of arterial stiffness can
capture CV risk from a genetic background and cumulative
damage from CV risk factors on the arterial wall. Recently, the
Reference Values for Arterial Stiffness Collaboration group in
Europe has published reference values for the PWV.13
Although normal PWV values might overlap between
younger and older individuals and many CV risk factors are
not all quantiﬁable (stress, positive family history, and others),
the mean normal value for individuals aged younger than 30
years is 6.2 m/s and for age 70 years and older is 10.9 m/s.13
Central BP might be a better predictor of target organ
damage than standard brachial BP. For example, it correlatesFigure 2. PWV and risk of a major CV event. The greater the PWV, the
greater is the risk of a major CV event over time. CV, cardiovascular;
PWV, pulse wave velocity. Data from Mitchell et al.11
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Potential Value of Central BPbetter with carotid internal diameter and intima-media thick-
ness than brachial BP measurements.14 The systolic augmen-
tation of central PP is associated with an increase in left
ventricular mass index independent of age and mean BP,15 and
carotid systolic BP is an independent determinant of left ven-
tricular wall thickness.16 Central pressure correlates more
closely with vascular hypertrophy and the extent of atheroscle-
rosis,14 and with CV risk in apparently healthy patients with
atherosclerotic disease.11 Increased central pressure is associated
with age-related macular degeneration17 and progression of
renal disease.18 In the Strong Heart study, a population-based
study of 3520 participants, central PP was more strongly
related to carotid artery vascular mass, intima-media thickness,
and carotid atherosclerotic plaque score than was brachial PP.19
In 2002, Safar and colleagues published the ﬁrst clinical
evidence of the prognostic value of the measure of aortic BP.20
In patients with end-stage renal disease, central PP measured
at the carotid artery was a found to be a signiﬁcant predictor
of all-cause mortality and CV mortality, and brachial PP had
no predictive value for mortality.20 In the Strong Heart study,
2403 participants free of CV events at baseline with a mean
follow-up of 4.8 years, the central PP predicted CV events
(myocardial infarction, coronary disease, heart failure, cardiac
death, and stroke) more strongly than brachial PP.19 In pa-
tients aged 65 years and older, including normotensive and
untreated hypertensive individuals followed over 8 years,
greater carotid PP at baseline, but not brachial PP, predicted
CV events and mortality.21 Kaess et al. prospectively investi-
gated the longitudinal and temporal relationships of vascular
hemodynamics in participants of the Framingham Offspring
cohort and found that higher aortic stiffness, forward wave
amplitude, and AIx were associated with a greater risk of
incident hypertension.22 Finally, Cheng et al. have recently
proposed that a diagnostic central BP number should be 
130/90 mm Hg.23Table 1. Effects of hypertension medications on wave reﬂection and
PWV








Angiotensin receptor antagonists Improvement Improvement
AIx, augmentation index; NC, no change; PWV, pulse wave velocity.Implications for Therapy
There is evidence that some antihypertensive agents might
provide target organ protection beyond their effect to decrease
brachial BP. Large multicentre trials comparing 2 active
treatments including the Second Australian National Blood
Pressure (ANBP2) study,24 Losartan Intervention for End
Point Reduction in Hypertension (LIFE),25 Anglo-Scandi-
navian Cardiac Outcomes Trial (ASCOT),26 and Avoiding
Cardiovascular Events Through Combination Therapy in
Patients Living With Systolic Hypertension (ACCOM-
PLISH)27 have shown clinical beneﬁts of BP-reducing
strategies including a calcium channel blocker or a renin-
angiotensin blocker (an angiotensin-converting enzyme in-
hibitor or an angiotensin receptor blocker) that were superior
to treatments based on a b-blocker (BB) or on a thiazide
diuretic for approximately the same level of peripheral
(brachial) BP. This added protection that goes beyond
brachial BP control could be explained by a neutral metabolic
effect of some antihypertensive agents, better tolerability, and
thus improved adherence. But a superior vascular protective
effect on target organs or on intermediate end points such as
arterial stiffness or central BP could be also related to a
reduced CV morbidity or mortality. Effects on central
pressures might not be evident according to pressuremeasurements of a peripheral (brachial) artery, because the
reﬂected wave is added to a different part of the central
waveform (ie, AIx). This might be one explanation as to why
drugs that provide similar reduction in peripheral pressures
have a different effect on CV outcome.
The largest randomized controlled trial conducted to test
the hypothesis of clinical beneﬁt of decreased central pressures
was the Conduit Artery Function Evaluation (CAFE) study, a
substudy of the ASCOT study.26 Radial artery applanation
tonometry and pulse wave analysis were used to derive central
aortic pressures and hemodynamic indices in 2199 patients
from the ASCOT study.28 Despite similar brachial systolic
BPs between treatment groups (D 0.7 mm Hg; P ¼ 0.2),
there were much larger reductions using the amlodipine-based
regimen in the central aortic systolic BP (D 4.3 mm Hg; P <
0.0001) and central aortic PP (D 3.0 mm Hg; P < 0.0001)
compared with the atenolol-based regimen. These greater re-
ductions in central pressures were associated with a signiﬁ-
cantly greater reduction in CV events and development of
renal impairment. The study was only hypothesis-generating
in this regard, but this degree of BP difference in addition
to the metabolic changes could have explained the different
outcomes between the 2 treatments, which produced essen-
tially the same brachial BP. Although central BP might be a
very useful index for CV risk assessment, it has not yet been
tested in a randomized controlled trial with clinical end points
and treatment guided by a central BP goal or arterial stiffness
markers. Recently, a randomized study29 has shown that using
central BP to guide the choice of antihypertensive therapy
leads to the use of less medication compared with the control
group of usual care in measuring arm BP.Antihypertensive Drugs and Arterial Stiffness
The effects of antihypertensive drugs on arterial stiffness
are complex and vary with time, the arterial territory studied,
and the distending pressure in the arteries. Their effect can be
direct (because of vascular smooth muscle relaxation) and
indirect (because of decreased wave reﬂection due to dilatation
of muscle arteries).30 A summary is provided in Table 1.
Thiazide diuretics generally have no effect on PWV and
arterial wave reﬂection.30-32 Some BBs have a favourable effect
on arterial stiffness measured according to a decrease in PWV
or wave reﬂection, but not consistently (Table 2). Atenolol
(compared with nitrendipine and fosinopril) and metoprolol
(compared with lisinopril) had no effect on PWV.33-35 When
comparing atenolol and metoprolol, the peripheral BP
reduction was the same, but the AIx increased with use of
atenolol.36 In contrast, bisoprolol reduced PWV in only some
Table 2. Effects of different b-blockers on wave reﬂection and PWV
b-Blocker Wave reﬂection (AIx) PWV
Propranolol NC NC
Atenolol NC Improvement




AIx, augmentation index; NC, no change; PWV, pulse wave velocity.
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PWV and AIx.37,38 Carvedilol (not approved in Canada for
hypertension) improved all central BP parameters but not as
well as losartan for the AIx.39 Calcium channel blockers,
speciﬁcally dihydropyridines, reduce PWV and wave reﬂec-
tion, but amlodipine has not been studied; data are limited for
nondihydropyridines.30 Renin-angiotensin blockers (angio-
tensin-converting enzyme inhibitors and angiotensin II
receptor antagonists) have been studied extensively. They
induce vasodilation, reverse vascular hypertrophy, and increase
arterial compliance. Globally, they all reduce the PWV and
the wave reﬂection.30 Finally, it is unclear if other medications
with vasodilatory effects (ie, clonidine, a-blockers, and hy-
dralazine) can improve central BP components. A summary is
provided in Tables 1 and 2.b-Blockers in Hypertension
The Canadian Hypertension Education Program recom-
mends the use of BBs as a ﬁrst line therapy for hypertension in
patients who have other compelling indications such as those
with coronary artery disease, who have had a myocardial
infarction, or heart failure.40 For hypertensive patients
without compelling indications in a primary prevention
setting, BBs are considered to provide the same CV protection
as other classes of antihypertensive medications in patients
younger than 60 years of age.Newer b-Blockers and Their Effect on Central
BP
All BBs reduce peripheral BP by blocking the b1 receptors
in the brain, heart, and kidneys, thereby decreasing cate-
cholamine outﬂow from the central nervous system, the force
and rate of cardiac contraction, and the release of renin.
Reduced renin will decrease the release of catecholamine and
aldosterone from the adrenal glands, the formation of angio-
tensin II, and arterial vasoconstrictive tone. With the avail-
ability of newer BBs with cardioselectivity and vasodilatory
capacities, the effect on central BP might be greater. Atenolol,
metoprolol, bisoprolol, and nebivolol are cardioselective and
labetolol, carvedilol, and nebivolol cause direct arterial vaso-
dilation; carvedilol does this by a a1-adrenergic blockade,
labetalol through a1-adrenergic blockade and by direct b2-
receptor stimulation, and nebivolol through unique nitric
oxide-mediated vasodilation that is endothelium-dependent.41
A number of studies suggest that newer BBs decrease
central BP parameters better than older BBs for similar re-
ductions in brachial BP. Shah et al. compared carvedilol with
atenolol in hypertensive individuals over 4 weeks and found
that despite equal BP-lowering, carvedilol resulted in a morefavourable PP ampliﬁcation and AIx by increasing arterial
compliance.42 In a double-blind randomized study, Dhakam
et al.43 compared the central hemodynamic effects of nebi-
volol with atenolol in previously untreated patients with iso-
lated systolic hypertension over 5 weeks. Despite similar
reductions in peripheral BP, nebivolol reduced central PP to a
greater extent than atenolol. Both drugs reduced aortic stiff-
ness, but nebivolol had less effect on the aortic AIx. In a
randomized double-blind study, Redón et al.44 treated
middle-aged hypertensive patients over 10 weeks with atenolol
or nebivolol. Brachial arterial pressure was decreased to the
same extent in both groups, but the AIx increased to a lesser
extent in the nebivolol group. Mean reductions of central
systolic BP were identical and central PP reduction showed a
trend in favour of nebivolol. In a longer study, Kampus
et al.45 compared metoprolol with nebivolol in a randomized
double-blind study in hypertensive subjects over 1 year. Heart
rate, brachial BP, and mean arterial pressure reductions were
identical. However, reductions in central systolic and diastolic
BPs, central PP, and left ventricular wall thickness were only
signiﬁcant in the nebivolol group. Finally, Vitale et al.46
compared the effects of nebivolol or irbesartan in combina-
tion with hydrochlorothiazide in patients with newly-
diagnosed hypertension. A similar, statistically signiﬁcant
reduction was observed for brachial BP, central BP and PP,
PWV, and AIx in both groups. Thus, so far, newer BBs have a
more favourable inﬂuence on arterial stiffness markers and
central BP, but clinical trials are needed to test the effect, if
any, of this difference on CV events.Conclusions
Arterial stiffness is now an established CV risk factor and
might prove to be a better risk index for target organ damage
and CV events in the hypertension population. Detection of
increased vascular stiffness can predict incident hypertension
in high-risk individuals and could serve as a marker of
inherent atherosclerotic risk. Central BP might have better
prognostic value than peripheral BP measurements because it
represents core BP to which heart, brain, and kidneys are
exposed. Antihypertensive medications vary in effects on
central BP and vascular stiffness, with particular heterogeneity
among BBs. It remains unclear whether the use of medications
to improve arterial stiffness or central BP values will translate
into better clinical outcomes. Randomized prospective
controlled studies comparing the effects on hard CV outcomes
for antihypertensive agents with different effects on central BP
are needed to answer this question.Acknowledgements
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